Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Glyoxal acid-free (GAF) histological fixative is a suitable alternative to formalin: results from an open-label comparative non-inferiority study

A. Ryska, A. Sapino, S. Landolfi, IS. Valero, SRY. Cajal, P. Oliveira, P. Detillo, L. Lianas, F. Frexia, PA. Nicolosi, T. Monti, B. Bussolati, C. Marchiò, G. Bussolati

. 2024 ; 485 (2) : 213-222. [pub] 20231124

Language English Country Germany

Document type Journal Article, Multicenter Study, Comparative Study, Equivalence Trial

Grant support
POR FESR 2014-2020 Regione Piemonte

E-resources Online Full text

NLK ProQuest Central from 2003-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2011-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest) from 2003-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2003-01-01 to 1 year ago

Formalin, an aqueous solution of formaldehyde, has been the gold standard for fixation of histological samples for over a century. Despite its considerable advantages, growing evidence points to objective toxicity, particularly highlighting its carcinogenicity and mutagenic effects. In 2016, the European Union proposed a ban, but a temporary permission was granted in consideration of its fundamental role in the medical-diagnostic field. In the present study, we tested an innovative fixative, glyoxal acid-free (GAF) (a glyoxal solution deprived of acids), which allows optimal tissue fixation at structural and molecular level combined with the absence of toxicity and carcinogenic activity. An open-label, non-inferiority, multicentric trial was performed comparing fixation of histological specimens with GAF fixative vs standard phosphate-buffered formalin (PBF), evaluating the morphological preservation and the diagnostic value with four binary score questions answered by both the central pathology reviewer and local center reviewers. The mean of total score in the GAF vs PBF fixative groups was 3.7 ± 0.5 vs 3.9 ± 0.3 for the central reviewer and 3.8 ± 0.5 vs 4.0 ± 0.1 for the local pathologist reviewers, respectively. In terms of median value, similar results were observed between the two fixative groups, with a median value of 4.0. Data collected indicate the non-inferiority of GAF as compared to PBF for all organs tested. The present clinical performance study, performed following the international standard for performance evaluation of in vitro diagnostic medical devices, highlights the capability of GAF to ensure both structural preservation and diagnostic value of the preparations.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019630
003      
CZ-PrNML
005      
20241024110618.0
007      
ta
008      
241015s2024 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00428-023-03692-6 $2 doi
035    __
$a (PubMed)37996705
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Ryska, Ales $u The Fingerland Department of Pathology, Charles University and Faculty Hospital, Hradec Kralove, Czech Republic
245    10
$a Glyoxal acid-free (GAF) histological fixative is a suitable alternative to formalin: results from an open-label comparative non-inferiority study / $c A. Ryska, A. Sapino, S. Landolfi, IS. Valero, SRY. Cajal, P. Oliveira, P. Detillo, L. Lianas, F. Frexia, PA. Nicolosi, T. Monti, B. Bussolati, C. Marchiò, G. Bussolati
520    9_
$a Formalin, an aqueous solution of formaldehyde, has been the gold standard for fixation of histological samples for over a century. Despite its considerable advantages, growing evidence points to objective toxicity, particularly highlighting its carcinogenicity and mutagenic effects. In 2016, the European Union proposed a ban, but a temporary permission was granted in consideration of its fundamental role in the medical-diagnostic field. In the present study, we tested an innovative fixative, glyoxal acid-free (GAF) (a glyoxal solution deprived of acids), which allows optimal tissue fixation at structural and molecular level combined with the absence of toxicity and carcinogenic activity. An open-label, non-inferiority, multicentric trial was performed comparing fixation of histological specimens with GAF fixative vs standard phosphate-buffered formalin (PBF), evaluating the morphological preservation and the diagnostic value with four binary score questions answered by both the central pathology reviewer and local center reviewers. The mean of total score in the GAF vs PBF fixative groups was 3.7 ± 0.5 vs 3.9 ± 0.3 for the central reviewer and 3.8 ± 0.5 vs 4.0 ± 0.1 for the local pathologist reviewers, respectively. In terms of median value, similar results were observed between the two fixative groups, with a median value of 4.0. Data collected indicate the non-inferiority of GAF as compared to PBF for all organs tested. The present clinical performance study, performed following the international standard for performance evaluation of in vitro diagnostic medical devices, highlights the capability of GAF to ensure both structural preservation and diagnostic value of the preparations.
650    12
$a formaldehyd $x chemie $7 D005557
650    _2
$a lidé $7 D006801
650    12
$a fixativa $x chemie $7 D005404
650    12
$a fixace tkání $x metody $7 D016707
650    12
$a glyoxal $7 D006037
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a srovnávací studie $7 D003160
655    _2
$a hodnocení ekvivalence $7 D000073843
700    1_
$a Sapino, Anna $u Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy $u Department of Medical Sciences, University of Turin, Turin, Italy
700    1_
$a Landolfi, Stefania $u Pathology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
700    1_
$a Valero, Irene Sansano $u Pathology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
700    1_
$a Cajal, Santiago Ramon Y $u Pathology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
700    1_
$a Oliveira, Pedro $u Department of Pathology, The Christie NHS Foundation Trust, Manchester, UK
700    1_
$a Detillo, Paolo $u ADDAX Biosciences Srl., Turin, Italy
700    1_
$a Lianas, Luca $u Data-Intensive Computing Division, Center for Advanced Studies, Research and Development in Sardinia (CRS4), Pula, Italy
700    1_
$a Frexia, Francesca $u Data-Intensive Computing Division, Center for Advanced Studies, Research and Development in Sardinia (CRS4), Pula, Italy
700    1_
$a Nicolosi, Pier Andrea $u 1MED SA, Agno, Switzerland
700    1_
$a Monti, Tommaso $u 1MED SA, Agno, Switzerland
700    1_
$a Bussolati, Benedetta $u Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
700    1_
$a Marchiò, Caterina $u Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy $u Department of Medical Sciences, University of Turin, Turin, Italy
700    1_
$a Bussolati, Gianni $u Department of Medical Sciences, University of Turin, Turin, Italy. gianni.bussolati@unito.it $1 https://orcid.org/0000000321755069
773    0_
$w MED00004660 $t Virchows Archiv : an international journal of pathology $x 1432-2307 $g Roč. 485, č. 2 (2024), s. 213-222
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37996705 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110612 $b ABA008
999    __
$a ok $b bmc $g 2202082 $s 1231603
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 485 $c 2 $d 213-222 $e 20231124 $i 1432-2307 $m Virchows Archiv : an international journal of pathology $n Virchows Arch $x MED00004660
GRA    __
$a POR FESR 2014-2020 $p Regione Piemonte
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...